[Limited surgical resection versus local endoscopic therapy of early cancers of the esophagogastric junction].
BACKGROUND
Adenocarcinomas of the esophagogastric junction (especially Barrett's cancers) are increasingly diagnosed at early stages. The current standard treatment - radical resection with extensive lymphadenectomy - has been challenged. Limited resection or endoscopic mucosal ablation have been proposed as less invasive alternatives.


METHODS
Available data regarding limited surgical resections and endoscopic interventional procedures are evaluated with respect to short- and long-term results (mortality, morbidity, oncologic adequacy, quality of life).


RESULTS
Limited resection of the esophagogastric junction has been proven as safe (low morbidity and mortality) and oncologically adequate procedure (low rate of recurrence/excellent long-term survival) with good quality of life. The procedure meets the oncological requirements (R0-resection, complete resection of potentially tumor-infiltrated lymph nodes and the entire precancerous Barrett's esophagus). Reconstruction with interposition of a pedicled isoperistaltic jejunal loop prevents reflux and is crucial for achieving good postoperative quality of life. In contrast, endoscopic mucosal resection (EMR) carries the risk of high recurrence rates (at least 30 %). This has to be regarded as an effect of the frequent incomplete resection, multicentric tumor growth, the persistence of precancerous Barrett's mucosa and persistence of gastroesophageal reflux. Consequently, from the oncological view point, EMR is only suited for unicentric mucosal tumors (T1a) in short segments of Barrett's esophagus. Reliable preoperative identification of such tumors is, however, currently not possible.


CONCLUSIONS
For adequately selected patients with early Barrett's cancer, limited resection of the esophagogastric junction is an appropriate procedure. Endoscopic mucosa resection (EMR) might gain importance as staging tool.
von Rahden
B H A
BH
Chirurgische Universitätsklinik, Paracelsus Medizinische Privatuniversität, Salzburg, Osterreich.
Feith
M
M
Stein
H J
HJ
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D001471:Barrett Esophagus / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016629:Esophagectomy; D004943:Esophagogastric Junction / Q000473:pathology / Q000601:surgery*; D004945:Esophagoscopy; D005500:Follow-Up Studies; D006801:Humans; D007583:Jejunum / Q000637:transplantation; D008197:Lymph Node Excision; D009092:Mucous Membrane / Q000473:pathology / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000601:surgery; D009367:Neoplasm Staging; D010043:Outcome and Process Assessment, Health Care; D011183:Postoperative Complications / Q000209:etiology / Q000601:surgery; D011230:Precancerous Conditions / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011788:Quality of Life; D015996:Survival Rate